Norway · Delayed Price · Currency is NOK PCI Biotech Holding ASA Company Description
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform.
The company’s technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities.
It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases.
PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.
| Country | Norway |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Ronny Skuggedal |
Contact Details
Address: Ullernchausséen 64 Oslo, 0379 Norway | |
| Phone | 47 67 11 54 00 |
| Website | pcibiotech.com |
Stock Details
| Ticker Symbol | PCIB |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010405640 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronny Skuggedal | Chief Executive Officer and Chief Financial Officer |
| Morten Luhr Ph.D. | Chief Scientific Officer |